TrialBMC medicine2025

Anti-PD1 antibody toripalimab combined with lenvatinib, or GEMOX chemotherapy combined with lenvatinib as first-line therapy in patients with advanced intrahepatic cholangiocarcinoma: a randomized, open, two-cohort Phase 2 Study.

Xiao-Yong Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.